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Background: Protein tyrosine phosphatase (PTP) 1B, a negative regulator of the insulin and leptin signaling
pathways, is currently considered a promising target for the development of novel therapeutic approaches used to
treat insulin-resistant type 2 diabetes mellitus (IR-T2DM). In this study, we examined the PTP1B inhibitory activity of
147 Japanese prescription Kampo formulations to evaluate their potential for clinical application in IR-T2DM
treatment.
Methods: We specifically defined the prescribed daily dose as 1 Unit (U), and 147 Japanese prescription Kampo
formulations were screened for PTP1B inhibitory activity at a final concentration of 0.1 mU/mL. We investigated the
dependence of the inhibitory activity on the concentration of the Kampo formulations that exhibited high PTP1B
inhibitory activity. Their inhibition mode by kinetic analysis, inhibitory selectivities against four homologous PTPs
(TCPTP, VHR, SHP-1 and SHP-2) and cellular activity in the insulin-signaling pathway by increasing the insulin-
stimulated Akt phosphorylation level in human hepatocellular liver carcinoma HepG2 cells, were also investigated.
The statistical partial least squares regression method was used to identify the crude drugs with the greatest
contribution to the PTP1B inhibitory activity of the Kampo formulations.
Results: Daiokanzoto, Masiningan, Tokakujokito, Keimakakuhanto and Choijokito exhibited high PTP1B inhibitory
activity, which was concentration-dependent. Daiokanzoto, Masiningan and Tokakujokito inhibited PTP1B by mixed
inhibition modes and exhibited different inhibitory selectivities against four homologous PTPs. Masiningan also
exhibited cellular activity. Statistical analyses indicated that the constituent crude drug Rhei Rhizoma provided the
greatest contribution to the PTP1B inhibitory activity of these Kampo formulations.
Conclusions: High PTP1B inhibitory activity was predominantly associated with formulations that were classified as
Jyokito in Kampo medicine and with a modern clinical indication of constipation. Currently, there is no clinical
treatment for IR-T2DM that uses a mechanism of action based on PTP1B inhibition. Thus, we propose the Kampo
formulations identified in this study as strong PTP1B inhibitors, which could be developed as clinical therapeutic
agents to treat IR-T2DM.
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The incidence of type 2 diabetes mellitus (T2DM) is
increasing worldwide [1]. A major subtype of T2DM is
insulin-resistant T2DM (IR-T2DM), which mainly de-
velops when insulin secretion in peripheral tissues is un-
able to compensate for insulin resistance [2]. IR-T2DM
is of importance because it is associated with multiple
complications such as cardiovascular anomalies [3]. Al-
though the first-line treatment for IR-T2DM usually in-
cludes a healthy diet and exercise, patients with diabetes
that cannot be controlled with healthy diet and exercise
alone are treated with drugs, such as sulfonylureas (SU),
dipeptidyl peptidase (DPP)-4 inhibitors, biguanides and
thiazolidine derivatives [4,5]. However, because of the ad-
verse effects and the presence of nonresponders, current
treatments using these drugs have been limited. For ex-
ample, pioglitazone, a thiazolidine derivative, which is
currently used widely in monotherapy or combination
therapy for IR-T2DM has serious adverse effects, includ-
ing angioneurotic edema and cardiac failure [6,7]. The
World Health Organization (WHO) has also recently re-
ported bladder cancer as a new side effect [8]. Thus, there
is a need to develop new approaches for the prevention
and treatment of IR-T2DM. Tyrosine phosphatase (PTP)
1B, which is a negative regulator of insulin and leptin sig-
naling pathways, is a promising target for the development
of IR-T2DM treatment.
PTP1B dephosphorylates the insulin receptor and lep-
tin receptor linked enzyme Janus kinase 2. It is an intra-
cellular phosphatase that is localized on the cytoplasmic
surface of the endoplasmic reticulum and is ubiquitously
expressed in insulin target tissues, such as liver, muscle
and adipose tissues [9]. PTP1B inhibition has been shown
in vivo to increase insulin and leptin activity and results in
normalized blood glucose levels and reduced adiposity
[10,11]. In addition, PTP1B inhibition may protect against
aging and has been studied from a broad perspective [12].
PTP1B inhibitors have gained much attention for their
therapeutic value associated with their novel mode of ac-
tion and are actively pursued in the development of new
drugs. Although some PTP1B inhibitors are undergoing
clinical trials, currently there are no PTP1B inhibitors
available for clinical use.
A total of 148 prescription Kampo formulations con-
sisting of 185 crude drugs are currently covered by Japan’s
national health insurance. There are 147 types of oral for-
mulations among 148 prescription Kampo formulations.
These Kampo formulations are in clinical use for a variety
of diseases, which are primarily based on traditional clin-
ical theories. However, due to the elucidation of the mech-
anisms of action of Kampo formulations in recent years,
evidence-based clinical applications are starting to be
developed, as exemplified by Daikenchuto [13]. Kampo
formulations consist of a combination of multiple crudedrugs and are characterized by their exertion of a thera-
peutic effect as a multicomponent system, in which func-
tional mechanisms of individual components are integrated.
Thus, it is difficult to understand the cause-and-effect rela-
tionships. However, we consider these formulations to be
beneficial for the treatment of metabolic disorders, such
as IR-T2DM, which require multiple therapeutic effects.
Kampo formulations, such as Goshajinkigan, can be used
for the treatment of diabetes complications, as demon-
strated by an in vivo study [14], and Bofutsushosan for the
prevention and treatment of obesity [15].
In this study, we report the results of an examination
of the PTP1B inhibitory activity of 147 Japanese prescrip-
tion Kampo formulations to evaluate their potential for
clinical application for the treatment of IR-T2DM.
Methods
Materials
This study examined 147 prescription Kampo formula-
tions, which represent the entire panel of oral Kampo
formulations covered by Japan’s national health insur-
ance. These formulations were manufactured by Tsumura
& Co. (Tokyo, Japan); Kotaro Pharmaceutical Co., Ltd.
(Osaka, Japan); Ohsugi Pharmaceutical Co., Ltd. (Osaka,
Japan); Kracie Holdings, Ltd. (Tokyo, Japan); Sanwa Shoyaku
Co., Ltd. (Tochigi, Japan); Taikoseido Pharmaceutical Co.,
Ltd. (Hyogo, Japan); or Toyo-Kampo Pharmaceutical Co.,
Ltd. (Osaka, Japan). Rhei Rhizoma and Cannabisi Fructus
were purchased from Tochimoto Tenkaido Co., Ltd.
(Osaka, Japan). PTP1B (human, recombinant), T-cell pro-
tein tyrosine phosphatase (TCPTP) (human, recombinant)
and Vaccinia H1-related phosphatase (VHR) (human, re-
combinant) were purchased from Enzo Life Sciences, Inc.
(Lausen, Switzerland), and ursolic acid (purity: 98.5%),
sodium orthovanadate (purity: 90%), citrate buffer so-
lution (pH 6.0), p-nitrophenyl phosphate (p-NPP), bovine
serum albumin, Src homology domain 2-Containing Pro-
tein Tyrosine Phosphatase 1 (SHP-1) and Src homology
domain 2-Containing Protein Tyrosine Phosphatase 2
(SHP-2) were obtained from Sigma-Aldrich Co., LLC.
(St Louis, MO, USA). Sodium chloride (NaCl), dithiothre-
itol (DTT), sodium hydroxide (NaOH), tris (hydroxy-
methyl) aminomethane, polyoxyethylene (23) lauryl ether
and insulin (human, recombinant) were purchased from
Wako Pure Chemical Industries, Ltd. (Osaka, Japan),
and ethylenediaminetetraacetic acid (EDTA) was obtained
from Dojindo Co., Ltd. (Kumamoto, Japan). Human hepa-
tocellular carcinoma cell lines were purchased from pG2
Japanese Cancer Research Resources Bank/Health Science
Research Resources Bank Co., Ltd. (Tokyo, Japan), and
fetal bovine serum was purchased from SAFC Biosciences,
Inc. (Lenexa, KS, USA). Dulbecco’s modified Eagle’s
medium (DMEM) was obtained from Nissui Co., Ltd.
(Tokyo, Japan). p-Akt1/2/3 (Ser 473) and Akt1/2/3
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biotechnology, Inc. (Dallas, TX, USA). Goat anti-rabbit
IgG-heavy and light chain antibody was purchased
from Bethyl Laboratories, Inc. (Montgomery, TX, USA).
Hybond-P PVDF membrane and ECL-plus were pur-
chased from GE Healthcare Life-Science Co., Ltd. (Tokyo,
Japan). PVDF Blocking Reagent, Can Get Signal Solution-I
and Can Get Signal Solution-II were purchased from
Toyobo Co., Ltd. (Tokyo, Japan). Anti-rabbit IgG-h + l
goat antibody was purchased from Bethyl laboratories Inc.
(Montgomery, TX).
Sample preparation of Kampo medicines
Each Kampo formulation was dissolved at 1/1,000 of the
daily dose (1 Unit), as indicated on the package insert,
in 1 mL of purified water, and extracted by sonication at
room temperature for 15 min. The mixture was then cen-
trifuged at 12,000 rpm for 15 min, and the supernatant or
supernatant diluent (in purified water) was used as the
sample for the PTP1B inhibitory activity assay.
Sample preparation of crude drugs
The crude drug of Rhei Rhizoma or Cannabisi Fructus
(60 g) was dissolved in distilled water (1,000 mL) and
decocted until the volume was reduced by half. The ex-
tract solutions were freeze-dried to obtain samples of
the crude drug.
PTP1B and other PTPs inhibitory activity assay
The PTP1B inhibitory activity was measured using p-
NPP as the substrate. Next, 40-μL solution of PTP1B or
VHR was dissolved in a buffer solution consisting of
0.06 M citric acid (pH 6.0), 0.1 M NaCl, 1 mM EDTA
and 1 mM DTT. For TCPTP, SHP-1 and SHP-2, assay
buffer (PH 7.0) was prepared using 25 mM Tris/HCl,
50 mM NaCl, 2 mM ethylenediaminetetraacetic acid,
5 mM dithiothreitol, 0.01% Brij35 and 1 mg/mL bovine
serum albumin; 50 μL of 2 mM p-NPP for PTP1B,
TCPTP, VHR and SHP-2; and 16 mM for SHP-1; and
10 μL of the sample or the sample diluent were added to
a 96-well plate (final volume, 100 μL). After incubation
at 37°C for 30 min, the reaction was terminated by add-
ing 20 μL of 10 M NaOH. The reaction mixture was
shaken on a microplate mixer for 30 s, and the amount
of p-nitrophenol produced was determined by measur-
ing the absorbance at 405 nm. The nonenzymatic hy-
drolysis of 2 mM p-NPP was corrected by measuring the
increase in absorbance at 405 nm, which was obtained
in the absence of PTP1B. In this study, ursolic acid, a
known PTP1B inhibitor, was used as the positive control
and exhibited an IC50 (50% inhibition concentration) of
4.3 μM, which was consistent with a previous report
[16].Inhibition rate and IC50
The inhibition rate of PTP1B activity of each sample was
determined on the basis of the p-nitrophenol production
measured as an increase in absorbance (ΔA) at 405 nm
of the sample solution over the initial 30 min, using the
following formula:
Inhibition rate %ð Þ ¼ 1‐ ΔAsample‐ΔAblank
 
ΔAcontrolð Þ  100
An inhibition rate of 90% or higher was considered
to indicate complete inhibition. The dependence of
the inhibitory activity on concentration was investigated
in Kampo samples that exhibited a complete inhibition
over a final concentration range from 0.1 mUnit/mL to
0.001 mUnit/mL. In addition, the crude drugs were in-
vestigated in the concentration range from 0.5 μg/mL to
100 μg/mL. The inhibition rate at each concentration
was then used to calculate the IC50 using linear regression
analysis.
Kinetics analysis
To elucidate the inhibition mode, the inhibition kinetics
of high PTP1B inhibitory Kampo samples (Daiokanzoto,
Masiningan and Tokakujokito) were analyzed using the
Lineweaver–Burk method with various substrate con-
centrations of p-NPP (2, 4, 8, 16 mM). The initial re-
action velocities were measured in the presence (the
concentration from 2 to 7 μUnit/mL) and absence of
the inhibitor [17].
Cytotoxicity assay
HepG2 cells was cultured in DMEM, supplemented with
10% heat-inactivated fetal bovine serum in a humidified
atmosphere containing 5% CO2 at 37°C. The cells were
incubated with the samples (Daiokanzoto, Masiningan,
Tokakujokito, Keimakakuhanto and Choijokito) from 0
to 50 mU/mL for three days. The number of living cells
was determined using the Premix WST-1 Cell Prolifera-
tion Assay System (TaKaRa, Shiga, Japan), according to the
manufacturer’s instructions.
Akt phosphorylation assay
HepG2 cells were cultured in DMEM, supplemented
with 10% heat-inactivated fetal bovine serum, at 37°C in
a humidified atmosphere containing 5% CO2. After pre-
treatment with each compound at 37°C for 60 min,
HepG2 cells (500 μL, 5 × 105 cells/well) in a 48-well
plate were stimulated with 50 nmol/L insulin for 5 min
at 37°C. After washing with cold phosphate buffered sa-
line, the cells were lysed using sonication. The lysate was
centrifuged at 15,000 rpm for 15 min, and the super-
natant was separated on 12% SDS-PAGE. After transfer
to a Hybond-P PVDF membrane, the membrane was
Table 1 The IC50 values of 22 Kampo prescriptions that
demonstrated significant PTP1B inhibitory activity
Kampo formula IC50 (μ Unit/mL)
a)
Daiokanzoto* 4.1 (± 0.08)
Masiningan* 4.3 (± 0.05)
Tokakujokito 4.9 (± 0.05)
Keimakakuhanto 6.3 (± 0.03)
Choijokito* 6.6 (± 0.09)
Bofutsushosan* 8.9 (± 0.08)
Daisaikoto 9.4 (± 0.06)
Kumibinroto 9.7 (± 0.63)
Kakkonto 9.7 (± 0.09)
Keishikashakuyakudaioto 10.2 (± 0.23)
Daijokito* 10.7(± 0.04)
Eppikajutsuto 11.6 (± 0.20)
Jidabokuippo 13.2 (± 0.04)
Tsudosan 13.8 (± 0.18)
Daisaikotokyodaio 14.0 (± 0.46)
Maoto 15.7 (± 0.18)
Kakkonkajutsubuto 15.7 (± 0.23)
Intinkoto 17.0 (± 0.20)
Maobushisaishinto 19.2 (± 0.16)
Kakkontokasenkyusini 19.8 (± 0.52)
Junchoto* 25.7 (± 0.94)
Keishito 29.5 (± 0.34)
Rhei Rhizoma 0.7 (± 0.02)c)
Cannabisi Fructus 51.6 (± 2.87)c)
Ursolic acidb) 4.3 (± 0.1)d)
The PTPlB inhibitory activity was significantly showed by 22 of the 147
Prescription Kampo Preparations. 22 prescriptions which showed high
inhibitory activity calculate IC50
a)Values are presented as mean ± SD, n = 3,
Unit means the weight of a given dose for one day. b)Positive control. c)IC50 in
μg/mL. d)IC50 in μM. *These are classified into “Jyokito” and the medicine of
relation in Chinese medicine.
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and was probed with 0.4 μg/mL anti-AKT1/2/3 rabbit
polyclonal antibody or anti-phosphorylated AKT1/2/3
rabbit polyclonal antibody in Can Get Signal Solution-I
for 1 h at room temperature, followed by further incuba-
tion with 0.025 μg/mL HRP-labeled anti-rabbit IgG-h + l
goat antibody in Can Get Signal Solution-II for 1 h at
room temperature. The membrane was then washed three
times with phosphate buffered saline-T, incubated with
ECL-plus for 5 min at room temperature and analyzed
using a Typhoon 9410. Sodium orthovanadate was used as
the positive control [18].
Partial least squares regression analyses
The partial least squares (PLS) regression method [19]
was used for statistical analysis of the contributions of
individual constituent crude drugs to the PTP1B inhibi-
tory activity of Kampo formulations. With each constituent
crude drug of the Kampo formulations as the regressor
variable (Xm) and the PTP1B inhibitory activity of the
Kampo formulations as the response variable (Y), we gen-
erated a regression formula to compare the contributions
from individual constituent crude drugs in this study, as
follows:
Y ¼ a0 þ a1X1 þ a2X2 þ a3X3 þ a4X4 þ⋯ þ amXm
þ f constantð Þ;
where m is the number of factors, n is the number of
samples, Y is the response variable, and X is the regres-
sor variable factor. The regression coefficient is a, and
its components are expressed as aj (j = 1 2 3…m).
In the PLS regression model, regression was per-
formed using the latent variable tk as the explanatory
variable by the following formula:
Y ¼ Y þ
XA
K¼1
tkqk þ e ¼ Y þ T ⋅q þ e




T þ E ¼ X þ T ⋅PT þ E;
where qk is the coefficient for the kth component in Y,
pk is the kth weight vector in X, A is the number of
latent variables for PLS, e is the difference of Y, and
E is the difference of X. Here, T represents a trans-
posed matrix. The number of latent variables for PLS,
A, was determined using the cross-validation method.
Cross-validation was performed as described below.
The n − 1 set consisting of n data subtracted from 1
set was used to estimate the model parameters. The
predictive value Ŷ for the response Y was obtained
for the 1 set that was subtracted. The same procedure







The number of components was selected in such a manner
that the predicted residual sum of squares (PRESS) was mini-
mized. In this study, statistical analysis was performed using
EXCEL Multivariate Analysis Ver. 6.0 (Esumi Co., Ltd.).
Results
PTP1B inhibitory activity screening of 147 Kampo
formulas
We screened the PTP1B inhibitory activity of all of the
147 oral Kampo formulations that are currently covered
by health insurance in Japan. For a better approximation
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PTP1B inhibitory activity of each Kampo formulation
based on the dose specified in the package inserts. We
specifically defined the prescribed daily dose as 1 Unit
(U) and 1/1,000 of this as 1 mU. Twenty-two of the 147
prescription Kampo formulations were demonstrated to
completely inhibit the PTP1B activity (inhibition of
>90%) at a final concentration of 0.1 mU/mL (Table 1).
Dose-dependent assay and IC50
We investigated the dependence of the inhibitory activity
on the concentration of 22 Kampo formulations that ex-
hibited high PTP1B inhibitory activity. These 22 Kampo
formulations were assayed for PTP1B inhibition at con-
centrations between 0.1 mU/mL and 0.001 mU/mL, and
all displayed concentration-dependent inhibitory activity
(Figure 1). To compare the inhibition potency of these
Kampo formulations, their IC50 values were determined
using the linear regression formula. Among the most potent
was Daiokanzoto, followed by Masiningan, Tokakujokito,
Keimakakuhanto and Choijokito.
Kinetics analysis
Daiokanzoto, Masiningan and Tokakujokito, which showed
more potent inhibitory activity, were selected for further
evaluation. Their inhibition mechanisms were elucidated
using kinetics analysis with various concentrations of
samples and the substrate, p-NPP. As shown in Figure 2,
Lineweaver-Burk plots indicated that they inhibited PTP1B
activity using mixed inhibition modes. However, the inhib-
ition modes of Daiokanzoto and Tokakujokito were more
non-competitive-like and Masiningan was competitive-
like.Figure 1 Samples inhibit PTP1B in a dose-dependent manner. Sample
of the samples (0.002 – 0.1 mUnit/mL) were evaluated using the in vitro PT
scale. The IC50 value was identified from the midpoint (cytotoxic activity =Inhibitory selectivity
Due to the high structural similarity of the catalytic cen-
ter among the family of protein tyrosine phosphatases
[20], the inhibitory selectivity of Daiokanzoto, Masinin-
gan and Tokakujokito were evaluated by comparing
their inhibitory activity against PTP1B and four homolo-
gous protein tyrosine phosphatases: TCPTP, VHR, SHP-
1 and SHP-2. At a final concentration of 25 μUnit/mL,
these samples fully inhibited PTP1B activity, but partially
inhibited other PTPs with different inhibition rate values:
73.6 – 82.4% against VHR, 57.0 – 62.4% against TC-PTP,
10.3 – 32.7% against SHP-1 and 9.0 – 9.2% for SHP-2
(Figure 3).
Cytotoxicity and Akt phosphorylation assay
On the basis of the enzymatic inhibition results, Daiokanzoto,
Masiningan, Tokakujokito, Keimakakuhanto and Choijokito
were further evaluated for their cellular activity in the insulin-
signal-transduction pathway in the human hepatocellular car-
cinoma cell line, HepG2, by measuring the phosphoryl-
ation level of Akt, a key downstream effector of the
insulin-signaling cascade. Because none of the samples
showed cytotoxicity at a final concentration of 50 mU/mL
in the Akt phosphorylation assay, the same sample con-
centration was used to assess their cellular activity in the
insulin-signal-transduction pathway. After the cells were
stimulated with insulin, the pAkt levels were analyzed
using western blotting at different times (0, 5 min), in
which water was used as a negative control. As shown
in Figure 4, the rapid and transient increase in pAkt
levels after insulin stimulation was promoted by the
administration of Masiningan, but not by the other four
samples.s inhibit PTP1B in a dose-dependent manner. Different concentrations
P1B enzyme assay. The dilution ratio is displayed on a logarithmic
50%) of the semi-log plot.
Figure 2 Lineweaver–Burk Plots of the top three Kampo formulations. Inhibition of PTP1B-catalyzed hydrolysis of p-NPP by Daiokanzoto,
Masiningan and Tokakujokito. Lineweaver–Burk plot of the effect of the Kampo formulations on PTP1B. The final concentrations of Daiokanzoto
were as follows: 0, 2, 3 and 7 μUnit/mL. The final concentrations of Masiningan were as follows: 0, 3, 5 and 6 μUnit/mL. The final concentrations
of Tokakujokito were as follows: 0, 3, 5 and 7 μUnit/mL.
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The Kampo formulations primarily exerted their activ-
ities via the combination of multiple crude drugs. A stat-
istical approach was used to identify the crude drugs
with the greatest contribution to the PTP1B inhibitory ac-
tivity of Kampo formulations that exhibited high PTP1BFigure 3 Selectivity of the top three Kampo formulations
against PTP1B, TCPTP, VHR, SHP-1 and SHP-2 at 25 μUnit/mL.
Inhibition selectivity of Daiokanzoto, Masiningan and Tokakujokito,
which shows high PTP1B inhibitory activity against PTP1B, TCPTP,
VHR, SHP-1 and SHP-2 at 25 μUnit/mL.inhibitory activity. Given the large number of crude drugs
constituting Kampo formulations and the colinearity ob-
served for high correlations between these crude drugs,
the five most potent Kampo formulations were selected
for PLS analysis to investigate the contribution of the con-
stituent crude drugs to PTP1B inhibition. We determined
the optimum latent variable using the cross-validation
model, and the coefficient of determination (R2) of the re-
gression model was 0.947. The experimental value, pre-
dictive value and difference for each Kampo formulation
are shown in Table 2. On the basis of the coefficients
obtained for individual crude drugs in the regression
model, Rhei Rhizoma exhibited the greatest contribu-
tion to PTP1B inhibitory activity among the 11 con-
stituent crude drugs (Table 3).
PTP1B inhibitory activity of crude drugs
To confirm the results obtained using the PLS method,
two crude drugs, Rhei Rhizoma and Cannabisi Fructus
were selected to determine their PTP1B inhibitory activ-
ity. In the PTP1B inhibitory activity assay, both lyophi-
lized decoctions of the crude drugs inhibited PTP1B
activity in a concentration-dependent manner, and their
IC50 values were calculated to be 0.7 and 51.6 μg/mL, re-
spectively (Table 1). Because Rhei Rhizoma showed much
more potent PTP1B inhibitory activity than Cannabisi
Fructus, it is consistent with the results obtained from the
statistical analysis.
Figure 4 Cellular activity of the Kampo formulations on Akt phosphorylation in HepG2 cells. Cellular activity of the Kampo samples, which
shows high PTP1B inhibitory activity, and water (negative control) on Akt phosphorylation in HepG2 cells.
Table 3 The regression coefficient of each constituent
crude drug obtained using the PLS method
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Screening of drugs already in clinical use represents an
optimal strategy used to identify a PTP1B inhibitor that
is effective as a therapeutic agent against IR-T2DM, al-
though no such drug is currently available for clinical
use. The Kampo formulations are among the most
promising candidates and are expected to exert inte-
grative therapeutic effects. In the present study, we
identified several Kampo formulations with high PTP1B in-
hibitory activity and Rhei Rhizoma as a constituent
crude drug with the greatest contribution to the inhibitory
activity.
High PTP1B inhibitory activity was associated with all of
the formulations classified in Kampo medicine as Jyokito
and its related formulations, including Daiokanzoto,
Masiningan and Tokakujokito (Table 1). Jyokito formulations
represent the most important group of prescription Kampo
formulations to ameliorate “Ki” symptoms. One such formu-
lation, Bofutsushosan, is already known to be effective for
the treatment of metabolic syndromes, such as IR-T2DM
and obesity [21]. The results from this study revealed the
PTP1B inhibitory effect as an unforeseen feature shared by
traditional Jyokito formulations.
The Kampo formulations, which exhibited the highest
PTP1B inhibitory activity may be beneficial for dia-
betes mellitus treatment, even within the current limited
scope of clinical application. For example, Daiokanzoto,Table 2 Predictive values of PTP1B inhibitory activity for









Daiokanzoto 4.1 4.4 −0.3
Masiningan 4.3 3.9 0.4
Tokakujokito 4.9 5.1 −0.2
Keimakakuhanto 6.3 6.3 0.0
Choijokito 6.6 6.4 0.2
Experimental value, Predictive value and Difference of each Kampo formula in
the latent variable obtained by the cross- validation method are shown. The
coefficient of determination in that case was 0.947. All values are expressed in
μUnit/mL. a)Difference = predicted - experimental.Masiningan and Tokakujokito are all effective for the
treatment of constipation, which is the most frequent
gastrointestinal symptom observed in diabetic patients
[22]. This represents a marked advantage in producing the
integrative therapeutic effects expected in the clinical use
of Kampo formulations.
Using the PLS method in multivariate analysis, Rhei
Rhizoma exhibited the greatest contribution to the PTP1B
inhibitory activity of Kampo formulations (Table 3), which
was further supported by the extract of Rhei Rhizoma
demonstrating more potent PTP1B inhibitory activity
compared to Cannabisi Fructus. The significant effect of
Rhei Rhizoma was demonstrated by comparing the PTP1B
inhibitory activity of Kampo formulations containing
highly related constituent crude drugs. Keishikashakuya-
kudaioto (IC50, 10.2 μUnit/mL) and Daisaikoto (IC50, 9.4
μUnit/mL) specifically exhibited higher inhibitory activity
compared to Keishikashakuyakukanzoto (IC50, inactive)
and Daisaikotokyodaio (IC50, 14.0 μUnit/mL). In addition
to our present study, other studies have reported that Rhei
Rhizoma is a beneficial crude drug for the amelioration of
metabolic diseases from various perspectives, including












The crude drugs with the regression coefficients of 0 > (a) are shown. The size
of a coefficient is reflected in a degree of incidence.
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Rhei Rhizoma may result in the discovery of new thera-
peutic agents for IR-T2DM. Such a finding could further
expand the potential of IR-T2DM treatment. Furthermore,
further understanding of how the Kampo drug functions
may be clarified by investigating reformulations of the
complex PTP1B-inhibiting crude drug compositions in
Kampo formulations.
Conclusions
In conclusion, we successfully identified Kampo formu-
lations with high PTP1B inhibitory activity from 147
prescription Kampo formulations. Although PTP1B is an
important target for the treatment of diabetes mellitus,
Kampo formulations exert their therapeutic effects via
multiple mechanisms of action. Nevertheless, our study
demonstrated the potential of concurrent assessments of
Kampo formulations for an action on a single target for
the purpose of identifying a candidate Kampo drug ef-
fective for the treatment of target-related diseases based
on relevant theories in Kampo medicine, current know-
ledge in modern medicine and relationships found
among constituent crude drugs from various perspec-
tives. This may represent an innovative step toward the
redefinition of the proper use of Kampo and the accu-
mulation of evidence. On the basis of the results of this
study, we are currently investigating how these candidate
Kampo formulations, which were identified in this study,
affect patients with IR-T2DM.
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